Vaxxas has initiated a multi-centre Phase 1 clinical trial of a vaccine against pre-pandemic avian influenza strain H7N9, using its high-density microarray patch.

Telix (ASX:TLX) has announced that the primary results from its Phase 3 ZIRCON trial have been published in The Lancet Oncology.

Australian clinical-stage biopharmaceutical company ENA Respiratory has been awarded an additional US$3.18 million contract from the US Department of Defense.

AusBiotech is pleased to announce the appointment of Tamlyn O’Connor as its new Industry Growth Program Manager.

Dimerix (ASX:DXB) has announced that the first patient has completed the ACTION3 Phase 3 clinical trial, including the initial follow-up period, and has chosen to enter the global open-label extension study.

Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19.

Nyrada (ASX:NYR) has provided an update on the development of its brain injury program with investigative first-in-class neuroprotection treatment, NYR-BI03.

Opthea (ASX:OPT) has announced executive leadership changes in finance and commercial and senior hires for biometrics, clinical operations and market access.

AusBiotech was pleased to be invited to participate in a HealthTech Roundtable and Business Luncheon with the Hong Kong Government’s Financial Secretary, Mr Paul Chan, and members to discuss growth opportunities for Australian biotech in Hong Kong and Asia.

CSL Limited (ASX:CSL) has announced the sale of its Wuhan Zhong Yuan Rui De Biologicals Products (Ruide) plasma collection and fractionation operations to Chengdu Rongsheng Pharmaceutical for USD$185 million in cash proceeds.

Lumos Diagnostics (ASX:LDX) has launched an equity offering that will raise up to approximately $10 million through a pro-rata accelerated non-renounceable entitlement offer.

Noxopharm (ASX:NOX) has announced progress on its Chroma technology platform, encouraging early drug leads with anticancer activity for glioblastoma and leukaemia.

MTPConnect has announced a new $28.5 million investment program supported by CSL and Roche Diagnostics for innovative small—and medium-sized enterprises developing innovative products targeting cardiovascular disease and diabetes.

The workshop, in partnership with Australia’s Chief Scientist Dr Cathy Foley, aims to accelerate the take-up of and build the demand for quantum technologies in Australia’s health sciences sector.

Percheron Therapeutics (ASX:PER) says preclinical data for its lead program, avicursen (ATL1102), further validates its pharmacological activity as an anti-inflammatory agent.

Australian company Emyria (ASX:EMD) has announced interim clinical results from an analysis of its MDMA-assisted therapy for post-traumatic stress disorder program, which commenced in October 2023.

Race Oncology (ASX:RAC) has announced that the first phase of the board renewal process, which commenced in 2023, is now complete with a newly appointed board.